August 14, 2018
Rose
Billionaire Carl Icahn had called the deal a "$60 billion folly," but is now walking back his opposition in light of recommendations from Institutional Shareholder Services and Glass Lewis. The latter called the insurer’s offer for the pharmacy benefits manager “both strategically and financially compelling, structured in a reasonable manner from a valuation standpoint for Cigna shareholders.”
from Kaiser Health News https://ift.tt/2Mm5wgx
August 14, 2018
Rose
Health News, Kaiser Health News
No comments
Related Posts:
School Districts Grapple With Quarantines, Face Masks And Fear- Five Years Later, HIV-Hit Town Rebounds. But The Nation Is Slow To Heed Lessons.
- Viewpoints: Lessons On Trying To Interpret Unreliable Data On Coronavirus; Every Candidate, Including Trump, Needs To Release Medical Records
- First Edition: February 19, 2020
- Analysis: Who Profits From Steep Medical Bills? The People Tasked With Fixing Them.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment